Yes I know, but with the camelid nanobodies the patient immune response to the nanobody is an issue - anytime you inject a foreign protein into a immune competent host you are going to get an immune reaction. It is very likely that i-bodies will face the same issue.
The post from Derek is just more to give a bit of background on why nanobodies haven't proven as successful as they might have been thought from 15 years ago. This all becomes important when 1AD goes looking for a pharma partner.
None of this suggests that 1AD is doomed, just that it has some serious obstacles on the way.
As an aside I happen to know Mick well and he is a very good scientist. I am not concerned about the quality of 1AD's science. I wish I could say that about all the biotechs listed on the ASX.
1AD Price at posting:
17.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)